Screener
Rapport Therapeutics, Inc. RAPP Balance Sheet Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $74.75M-70.3% | $63.61M+15.5% | $78.06M+35.5% | $52.65M-7.3% | $251.36M+539% | ||
| $320.28M+22.4% | $372.47M+81.4% | $398.73M+75.1% | $437.89M+76.2% | $261.67M-7.0% | ||
| $171K— | $293K— | $58K— | $0— | —— | ||
| $407.38M-21.8% | $446.86M+65.4% | $484.7M+66.6% | $498.56M+60.9% | $520.66M+59.7% | ||
| $1.96M-37.2% | $2.34M-26.3% | $2.52M-26.0% | $2.98M-15.7% | $3.12M-8.6% | ||
| $418.56M-21.8% | $458.98M+60.8% | $497.6M+64.7% | $512.43M+62.7% | $535.32M+61.7% | ||
| $1.72M-46.9% | $2.8M-12.0% | $6.56M+207% | $4.19M+114% | $3.24M+145% | ||
| $20.3M+41.8% | $28.42M+139% | $17.9M+90.7% | $19.05M+117% | $14.32M+102% | ||
| $27.37M+15.4% | $36.06M+64.0% | $26.09M+60.8% | $27.78M+192% | $23.71M+195% | ||
| $48K0.0% | $48K+29.7% | $48K+29.7% | $48K+29.7% | $48K+33.3% | ||
| -$351.94M-74.7% | -$311.7M-78.6% | -$255.09M-72.6% | -$235.23M-90.1% | -$201.47M-94.2% | ||
| $391.19M-23.5% | $422.93M+60.5% | $471.51M+65.0% | $484.65M+58.7% | $511.62M+58.3% | ||
| $418.56M-21.8% | $458.98M+60.8% | $497.6M+64.7% | $512.43M+62.7% | $535.32M+61.7% |
FAQ
- What are Rapport Therapeutics, Inc.'s total assets?
- Rapport Therapeutics, Inc. (RAPP) holds $418.6M in total assets, down 21.8% year over year.
- How much debt does Rapport Therapeutics, Inc. have?
- Rapport Therapeutics, Inc. carries $9.4M in total debt against $391.2M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Rapport Therapeutics, Inc. have?
- Rapport Therapeutics, Inc. holds $74.8M in cash and equivalents.
- Can Rapport Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 20.07 — current assets exceed current liabilities.
- Where does Rapport Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.